Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer

por Chen, Li-Tzong, Macarulla, Teresa, Blanc, Jean-Frédéric, Mirakhur, Beloo, de Jong, Floris A., Belanger, Bruce, Bekaii-Saab, Tanios, Siveke, Jens T.
Publicado 2019

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

por Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Völkel, Dirk, Youssef, Ashraf, de Jong, Floris A., Tsimberidou, Apostolia Maria
Publicado 2020

Effects of methimazole on the elimination of irinotecan

por van der Bol, Jessica M., Visser, Theo J., Loos, Walter J., de Jong, Floris A., Wiemer, Erik A. C., van Aken, Maarten O., Planting, Andre S., Schellens, Jan H., Verweij, Jaap, Mathijssen, Ron H. J.
Publicado 2010

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST an...

por Pelzer, Uwe, Blanc, Jean-Frédéric, Melisi, Davide, Cubillo, Antonio, Von Hoff, Daniel D, Wang-Gillam, Andrea, Chen, Li-Tzong, Siveke, Jens T, Wan, Yin, Solem, Caitlyn T, Botteman, Marc F, Yang, Yoojung, de Jong, Floris A, Hubner, Richard A
Publicado 2017